Form 4: Karyopharm Officer Sells Shares for Tax After PSU Vesting

Karyopharm Therapeutics' Chief Accounting Officer, Kristin Abate, acquired 92 shares from vested performance-based restricted stock units and subsequently sold 50 shares to cover tax obligations.

Summary

• Kristin Abate, Chief Accounting Officer of Karyopharm Therapeutics Inc. (KPTI), acquired 92 shares of common stock on January 27, 2026.
• These shares represent performance-based restricted stock units (PSUs) granted in February 2023, which vested on January 27, 2026, after achieving revenue and total shareholder return milestones.
• Abate then sold 50 shares of common stock on January 28, 2026, at a price of $7.03 per share.
• This sale was executed under a pre-arranged 10b5-1 plan adopted on May 27, 2021, specifically to satisfy withholding tax liabilities incurred from the PSU vesting.
• The transaction was not a discretionary trade by the reporting person.
• Following these transactions, Abate beneficially owns 22,622 shares of Karyopharm Therapeutics common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. The vesting of PSUs indicates Karyopharm met performance milestones, which is positive. The subsequent sale is a routine tax-related transaction and not a discretionary sell-off.

Positives

• The vesting of performance-based restricted stock units (PSUs) indicates the achievement of revenue and total shareholder return milestones, suggesting positive operational and market performance for Karyopharm Therapeutics.

Negatives

• The sale of shares, even for tax purposes, reduces the insider's direct equity stake in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider sales for tax purposes following equity vesting are common across the biotechnology and pharmaceutical industries, particularly for executives compensated with performance-based equity. This transaction does not inherently signal a change in company fundamentals or management's long-term outlook, but rather a standard compensation event.

Comparison to Industry Standards

• This type of transaction, where an executive sells a portion of vested equity to cover tax obligations, is a standard practice in executive compensation across publicly traded companies, including those in the biotech sector like Moderna or Pfizer.
• It is not indicative of a discretionary investment decision but rather a pre-planned event to manage tax liabilities associated with equity awards.
• No specific comparable companies or projects are directly relevant for this routine tax-related sale.

Stakeholder Impact

• Shareholders: The achievement of performance milestones for PSU vesting could be seen positively, indicating company performance. The tax-related sale is a routine event and generally has minimal impact on shareholder sentiment.
• Employees: The vesting of PSUs for an executive reinforces the company's compensation structure tied to performance.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary insider transaction where an executive sold shares to cover tax liabilities upon the vesting of performance-based restricted stock units. While the vesting itself implies the achievement of company milestones, the sale is not indicative of a change in the company's fundamental outlook or a discretionary move by the insider. Therefore, it does not provide new information that would warrant a change in investment recommendation; a 'hold' stance is appropriate as this is a neutral event.

Keywords

Karyopharm Therapeutics, KPTI, Kristin Abate, Insider Trading, Form 4, Stock Sale, PSU Vesting, Restricted Stock Units, 10b5-1 Plan, Chief Accounting Officer